Efficiency in the treatment of juvenile rheumatoid arthritis

The medical and economic efficiency of various treatment programs for juvenile rheumatoid arthritis is analyzed. The use of tocilizumab is 1.9 times more effective than in the group with traditional treatment. Evaluation of the quality of life of patients with juvenile rheumatoid arthritis on the SF-36 scale can be used to assess the effectiveness of treatment by parameters reflecting the physical, psycho-emotional state and social adaptation of the child. The authors note the smallest amount of costs per unit of quality of life of the patient in the tocilizumab treatment program.